Surgery
Clinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases
Annals of Surgical Oncology 2025 July [Link] He-Liang Wu, Rui Yang, Xin-Li Liang, Ru Ma, Yan-Dong Su, Zhi-Ran Yang, Yu-Run Cui, Xue-Mei Du, Yi-Tong Liu, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with high mortality rate and extremely poor prognosis. The tumor immune microenvironment, particularly tumor-infiltrating lymphocytes (TILs), plays…
Read MorePD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Cancer Research Communications 2025 May 1 [Link] Gwendolyn M Cramer, Richard W Davis 4th, Emmanouil Papasavvas, Astero Klampatsa, Joann M Miller, Shirron Carter, Ruth Ikpe, Min Yuan, Sandy Widura, R Sonali Majumdar, Sally McNulty, Mary Putt, Andrew V Kossenkov, Luis J Montaner, Sunil Singhal, Edmund K Moon, Steven M Albelda, Keith A Cengel, Theresa M…
Read MoreEnhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MoreOncological Outcomes Of Radical Surgery With And Without Induction And Adjuvant Chemotherapy In Mesothelioma Patients – 8-Year Experience In A Single Center
Portuguese Journal of Cardiac Thoracic & Vascular Surgery 2025 April 29 [Link] Agata Nawojowska, Samuel Mendes, Marion Gaspar, Daniel Cabral, Cristina Rodrigues, Mariana Antunes, Magda Alvoeiro, Telma Calado, Francisco Félix Abstract Introduction: Mesothelioma is a devastating, insidious disease with a long latency period. Its peak incidence occurs in the 5th and 6th decades of life,…
Read MoreThe Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Cancers 2025 April 20 [Link] Berta Mosleh, Katharina Sinn, Anna Cho, Anton Reiner, Ariane Steindl, Christian Lang, Sabine Zöchbauer-Müller, Karin Dieckmann, Joachim Widder, Helmut Prosch, Balazs Dome, Karin Schelch, Clemens Aigner, Thomas Klikovits, Michal Benej, Stefan Watzka, Martin Filipits, Servet Bölükbas, Pavla Sarova, Daniela Gompelmann, Michael Grusch, Mir Alireza Hoda Abstract Background/objectives: Malignant pleural mesothelioma…
Read MoreHyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review
World Journal of Surgical Oncology 2025 April 9 [Link] Hany Hasan Elsayed, Mohamed Elanany Elsaid Elanany, Mohamed Tarek ElSayegh, Aly Sherif Hassaballa, Mohammed Abdel-Gayed Abstract Surgery-based multimodality therapies for treatment of malignant pleural mesothelioma have been clinically explored in the past decades. In this regard, hyperthermic intrathoracic or intrapleural chemotherapy has been used as one…
Read MorePotential advantage of magnetic resonance imaging in detecting thoracic wall infiltration in pleural mesothelioma: A retrospective single-center analysis
JTCVS Open 2024 October 22 [Link] Isabel Barreto, Sabine Franckenberg, Thomas Frauenfelder, Isabelle Opitz, Olivia Lauk Abstract Objectives: Thoracic wall infiltration in pleural mesothelioma determines the extent of resection and can be an important prognostic factor. Currently, standardized imaging for restaging after neoadjuvant systemic therapy comprises contrast-enhanced computed tomography or positron emission tomography. Additional thoracic…
Read MoreImpact of Neoadjuvant and Adjuvant Pleural Intensity-Modulated Radiotherapy in Multimodality Treatment for Malignant Pleural Mesothelioma
Thoracic Cancer 2025 March [Link] Berta Mosleh, Stefan Schwarz, Anna Cho, Katharina Sinn, Ariane Steindl, Sabine Zöchbauer-Müller, Wolfgang J Köstler, Karin Dieckmann, Martin Heilmann, Joachim Widder, Daniela Gompelmann, Clemens Aigner, Thomas Klikovits, Mir Alireza Hoda Abstract Background: Few malignancies provoke as many controversies about treatment as pleural mesothelioma. There is limited experience with novel radiotherapy…
Read MorePrognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BMC Cancer 2025 February 14 [Link] Zhang Xinjing, Gong Lei, Li Xinbao, Ji Zhonghe, Yang Zhiran, Gao Chao, Zhang Kai, Yan Lijun, Yan Guojun, Yu Junhui, Zhang Yanbin, An Songlin Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for…
Read MoreCurrent Status of Staging and Restaging Malignant Pleural Mesothelioma
Seminars in Nuclear Medicine 2025 March [Link] Egesta Lopci Malignant pleural mesothelioma (MPM) is the most frequent aggressive tumor affecting the pleura, accounting for over 38,000 deaths worldwide. It originates from the mesothelial cells and is mostly associated to asbestos exposure. Depending on the extent of the disease, the management of MPM varies from surgical…
Read More